Terms: = Thyroid cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
359 results:
1. Augmented ERO1α upon mtorC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11.
Wang Z; Zong H; Liu W; Lin W; Sun A; Ding Z; Chen X; Wan X; Liu Y; Hu Z; Zhang H; Li H; Liu Y; Li D; Zhang S; Zha X
J Exp Clin Cancer Res; 2024 Apr; 43(1):112. PubMed ID: 38610018
[TBL] [Abstract] [Full Text] [Related]
2. ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway.
Zhou X; Zhao J; Yan T; Ye D; Wang Y; Zhou B; Liu D; Wang X; Zheng W; Zheng B; Qian F; Li Y; Li D; Fang L
Cell Death Dis; 2024 Apr; 15(4):260. PubMed ID: 38609357
[TBL] [Abstract] [Full Text] [Related]
3. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mtor pathway.
Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
[TBL] [Abstract] [Full Text] [Related]
4. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mtor signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
5. TMEM97 knockdown inhibits 5-fluorouracil resistance by regulating epithelial-mesenchymal transition and ABC transporter expression via inactivating the Akt/mtor pathway in 5-fluorouracil-resistant colorectal cancer cells.
Xu Y; Tang Y; Xu Q; He W
Chem Biol Drug Des; 2024 Feb; 103(2):e14490. PubMed ID: 38388887
[TBL] [Abstract] [Full Text] [Related]
6. Deep response to a combination of mtor inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
7. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mtor pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract] [Full Text] [Related]
8. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
Zhang X; Zhang L; Wang B; Zhang X; Gu L; Guo K; Zhang X; Zhou Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):221-225. PubMed ID: 38279433
[TBL] [Abstract] [Full Text] [Related]
9. Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.
Lee M; Morris LG
Oncotarget; 2024 Jan; 15():36-48. PubMed ID: 38275291
[TBL] [Abstract] [Full Text] [Related]
10. The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mtor signaling.
Huang M; Yu X; Wang Q; Jiang Z; Li X; Chen W; Song C
Cell Commun Signal; 2024 Jan; 22(1):35. PubMed ID: 38216949
[TBL] [Abstract] [Full Text] [Related]
11. DT-13 inhibits the proliferation of pancreatic cancer by inducing apoptosis via AMPK-mtor signaling.
Xie G; Tong F; Xu M; Shu Y; Li Z
Biochem Biophys Res Commun; 2024 Feb; 695():149451. PubMed ID: 38176173
[TBL] [Abstract] [Full Text] [Related]
12. Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.
Guo Y; Cui J; Liang X; Chen T; Lu C; Peng T
Int Immunopharmacol; 2024 Jan; 127():111407. PubMed ID: 38134594
[TBL] [Abstract] [Full Text] [Related]
13. Characterization of the genomic alterations in poorly differentiated thyroid cancer.
Lee Y; Moon S; Seok JY; Lee JH; Nam S; Chung YS
Sci Rep; 2023 Nov; 13(1):19154. PubMed ID: 37932340
[TBL] [Abstract] [Full Text] [Related]
14. Identification of a Novel TSC2 c.170G>A Missense Variant: A Case Report and Elaboration on the Yield of Targeted Options against Tuberous Sclerosis Complex Manifestations.
Papageorgiou G; Skouteris N; Valavanis C; Stanc GM; Souka E; Charalampakis N
Rev Recent Clin Trials; 2023; 18(4):304-312. PubMed ID: 37877150
[TBL] [Abstract] [Full Text] [Related]
15. Circular RNAs: characteristics, functions, mechanisms, and potential applications in thyroid cancer.
Wu M; Yuan H; Zou W; Xu S; Liu S; Gao Q; Guo Q; Han Y; An X
Clin Transl Oncol; 2024 Apr; 26(4):808-824. PubMed ID: 37864677
[TBL] [Abstract] [Full Text] [Related]
16. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.
Qiao L; Dong C; Jia W; Ma B
Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
[TBL] [Abstract] [Full Text] [Related]
17. Study of the PI3K/Akt/mtor signaling pathway in vitro and molecular docking analysis of periplocin inhibits cell cycle progression and induces apoptosis in MDA-MB-231.
Liu X; Liu J; Yan B; Quan Z; Wang X; Ma Y; Alarfaj AA; Yan L
Environ Toxicol; 2024 Jan; 39(1):444-456. PubMed ID: 37792628
[TBL] [Abstract] [Full Text] [Related]
18. Spleen tyrosine kinase facilitates the progression of papillary thyroid cancer regulated by the hsa_circ_0006417/miR-377-3p axis.
Tan G; Zheng S; Zhou B; Mo Z; Zhang Q; Zhang D; Li A; Liu X
Environ Toxicol; 2024 Jan; 39(1):421-434. PubMed ID: 37792549
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive pan-cancer analysis of expression profiles and prognostic significance for NUMB and NUMBL in human tumors.
Zhang Y; Yang H; Liu W; Song Q; Li Y; Zhang J; Zhou D; Li A
Medicine (Baltimore); 2023 Sep; 102(35):e34717. PubMed ID: 37657045
[TBL] [Abstract] [Full Text] [Related]
20. A cleaved METTL3 potentiates the METTL3-WTAP interaction and breast cancer progression.
Yan C; Xiong J; Zhou Z; Li Q; Gao C; Zhang M; Yu L; Li J; Hu MM; Zhang CS; Cai C; Zhang H; Zhang J
Elife; 2023 Aug; 12():. PubMed ID: 37589705
[No Abstract] [Full Text] [Related]
[Next]
